Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Zantac who wrote (1096)	3/19/2001 2:45:08 PM
From: Bosco	Respond to of 1298

Hi Zantac - I am bullish on CEGE, but where did you get the $23/shr cash figure? I ve $7 - $8 as of last Q, not including the buildout Thx best, Bosco

To: Zantac who wrote (1096)	3/19/2001 3:05:03 PM
From: Londo	Read Replies (1) \| Respond to of 1298

Your numbers are incorrect; look at the balance sheet ending December 31, 2000: $260M cash, 8.95M shares ABGX.. ABGX = ~$20/share, so that leaves marketable securities of roughly $180M, so total net cashable assets are $440M or roughly $12.50/share. That said, the rest of your reasoning is perfectly correct.. these guys are expanding their clinical trials, expanding manufacturing capabilities (buying that plant from Chiron was a steal), and growing other businesses.. This company will make it big, under the big "if".. gene therapy has to be for 'real'.